Seattle Genetics, Inc.(SGEN)

Description: Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

---

Keywords: Medicine Biotechnology Cancer Solid Tumors Nasdaq 100 Treatment Of Cancer Monoclonal Antibodies Chemotherapy Prostate Cancer Lymphoma Monoclonal Antibody Genetics Pancreatic Cancer Carcinoma Hematologic Malignancies Renal Cell Carcinoma Antibody Drug Conjugate Therapies For Cancer CD19 Non Hodgkin Lymphoma Resistant Prostate Cancer Hodgkin Lymphoma Metastatic Pancreatic Cancer Castration Resistant Prostate Cancer Chemotherapy Regimen Positive Solid Tumors Cd30

---

Home Page: www.seagen.com

SGEN Technical Analysis

21823 30th Drive SE
Bothell, WA 98021
United States
Phone: 425 527 4000

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)